Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human safety and pharmacokinetics of topical CEE321 0.2% cream in adults
jRCT2031200317Phase 1Completed
- Sponsor
- Novartis
- Start
- Jan 2021
- Modality
- Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 1 trial of CEE321 in atopic dermatitis (AD) (2 arms), sponsored by Novartis. Primary endpoint: Number of subjects with adverse events. Started Jan 2021; status: completed.
02
Drugs
CEE321
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031200317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200317.